Ernexa Therapeutics Inc(ERNA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 13 at 6:44 PM ET (Korea 11/14 08:44)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -17.04 | Insider Own | 30.04% | Shs Outstand | 1.6M | Perf Week | -10.64% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.2M | Perf Month | -22.58% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 8.07% | Short Float | 2.82% | Perf Quarter | -58.62% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -12.9% | Short Ratio | 0.73 | Perf Half Y | -87.67% |
| Sales | 0.00B | P/B | 0.64 | EPS next 5Y | - | ROA | -210.27% | Short Interest | 0.03M | Perf YTD | -94.4% |
| Book/sh | 2.64 | P/C | 0.51 | EPS past 3/5Y | 73.56% 69.9% | ROE | -352.43% | 52W High | -95.83% ($40.24) | Perf Year | -95.72% |
| Cash/sh | 3.3 | P/FCF | - | Sales past 3/5Y | - | ROIC | -310.94% | 52W Low | -3.13% ($1.73) | Perf 3Y | -99.61% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 85.64% | Gross Margin | - | Volatility(W/M) | 13.22% 9.82% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.23 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 2.57 | EPS Q/Q | 49.97% | Profit Margin | - | RSI (14) | 31.22 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.57 | Sales Q/Q | - | SMA20 | -15.13% ($1.98) | Beta | 2.74 | Target Price | $30 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/08/17 | SMA50 | -38.85% ($2.75) | Rel Volume | 0.62 | Prev Close | $1.79 |
| Employees | 5 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | - | SMA200 | -71.74% ($5.94) | Avg Volume(3M) | 0.05M | Price | $1.68 |
| IPO | 1991/8/29 | Option/Short | No/Yes | Trades | 196 | Volume | 28,264 | Change | -6.15% |
🧬 Anexa Therapeutics () is a preclinical-stage biotech developing cell therapies based on induced mesenchymal stem cells (iMSCs) differentiated from induced pluripotent stem cells. Founded in 2018 and headquartered in Cambridge, Massachusetts, USA, the company changed its name from Eterna Therapeutics in March 2025. Its two core pipeline programs are ERNA-101, targeting ovarian cancer, and ERNA-201, targeting rheumatoid arthritis.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded less than usual. That is 62% of its average volume.
ERNA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +61% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 8.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
VXUS Vanguard Total International Stock ETF 161.7B 
BNDX Vanguard Total International Bond ETF 85.0B 
SCHF Schwab International Equity ETF 67.9B 
IXUS iShares Core MSCI Total International Stock ETF 57.6B 
BIV Vanguard Intermediate-Term Bond ETF 28.5B It ranks #563 of 598 in the industry
Based on market cap of $3M.
CRIS#560 Curis Inc $3M PER - 
SILO#561 SILO Pharma Inc $3M PER - 
REVB#562 Revelation Biosciences Inc $3M PER - ERNA#563 Ernexa Therapeutics Inc $3M PER - 
KALA#564 Kala Bio Inc $3M PER - 
FAQ
What kind of company is ERNA?
ERNA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ERNA?
The market cap of ERNA is approximately $3M, ranking 5,728 within its sector.
What is the 52-week high and low for ERNA?
ERNA has recorded a 52-week high of $40.24 and a low of $1.73.
